Using Cheminformatics in Drug Discovery

  • Michael S. LawlessEmail author
  • Marvin Waldman
  • Robert Fraczkiewicz
  • Robert D. Clark
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 232)


This chapter illustrates how cheminformatics can be applied to designing novel compounds that are active at the primary target and have good predicted ADMET properties. Examples of various cheminformatics techniques are illustrated in the process of designing inhibitors that inhibit both cyclooxygenase isoforms but are more potent toward COX-2. The first step in the process is to create a knowledge database of cyclooxygenase inhibitors in the public domain. This data was analyzed to find activity cliffs – small structural changes that result in drastic changes in potency. Additional cyclooxygenase potency and selectivity trends were obtained using matched molecular pair analysis. QSAR models were then developed to predict cyclooxygenase potency and selectivity. Next, computational algorithms were used to generate novel scaffolds starting from known cyclooxygenase inhibitors. Nine virtual libraries containing 240 compounds each were constructed. Predictions from the cyclooxygenase QSAR models were used to eliminate molecules with undesirable potency or selectivity. Additionally, the compounds were screened in silico for undesirable ADMET properties, e.g., low solubility, permeability, metabolic stability, or high toxicity, using a liability scoring system known as ADMET Risk™. Eight synthetic candidates were identified from this process after incorporating knowledge gained from activity cliff analysis. Four of the compounds were synthesized and tested to measure their COX-1 and COX-2 IC50 values as well as several ADME properties. The best compound, SLP0020, had a COX-1 IC50 of 770 nM and COX-2 IC50 of 130 nM.


Activity cliffs ADMET Combinatorial design COX-1 COX-2 Cyclooxygenase Drug design Matched molecular pairs QSAR QSPR Scaffold hopping 


  1. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A et al (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) programme: a randomized comparison. Lancet 386:1771–1781CrossRefGoogle Scholar
  2. Chavatte P, Yous S, Marot C, Baurin N, Lesieur D (2001) Three-dimensional quantitative structure-activity relationships of cyclo-oxygenase-2 (COX-2) inhibitors: a comparative molecular field analysis. J Med Chem 44:3223–3230CrossRefPubMedGoogle Scholar
  3. Conaghan PG (2012) A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int 32:1491–1502CrossRefPubMedPubMedCentralGoogle Scholar
  4. Dearden JC, Cronin MTD, Kaiser KLE (2009) How not to develop a quantitative structure-activity or structure–property relationship (QSAR/QSPR). SAR QSAR Environ Res 20:241–266CrossRefPubMedGoogle Scholar
  5. Friesen RW, Brideau C, Chan CC, Charleson S, Deschanes D et al (1998) 2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 8:2777–2782CrossRefPubMedGoogle Scholar
  6. Gaulton A, Bellis L, Chambers J, Davies M, Hersey A et al (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40(Database Issue):D1100–D1107CrossRefPubMedPubMedCentralGoogle Scholar
  7. Glaser K, Sung ML, O’neill K, Belfast M, Hartman D et al (1995) Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 281:107–111CrossRefPubMedGoogle Scholar
  8. Lewell XQ, Judd DB, Watson SP, Hann MM (1998) RECAP – retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J Chem Inf Comput Sci 38:511–522CrossRefPubMedGoogle Scholar
  9. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3–26CrossRefGoogle Scholar
  10. Maggiora GM (2006) On outliers and activity cliffs - why QSAR often disappoints. J Chem Inf Model 46:1535CrossRefPubMedGoogle Scholar
  11. Maxwell SR, Webb DJ (2005) COX-2 selective inhibitors - important lessons learned. Lancet 365:449–451CrossRefPubMedGoogle Scholar
  12. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW et al (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem 40:1347–1365CrossRefPubMedGoogle Scholar
  13. Prasit P, Wang Z, Brideau C, Chan C, Charleson S et al (1999) The discovery of rofecoxib, [MK 966, vioxx, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5h)-furanone], an orally active cyclooxygenase-2 inhibitor. Bioorg Med Chem Lett 9:1773–1778CrossRefPubMedGoogle Scholar
  14. Scior T, Medina-Franco JL, Do QT, Martinez-Mayorga K, Yunes Rojas JA, Bernard P (2009) How to recognize and workaround pitfalls in QSAR studies: a critical review. Curr Med Chem 16:4297–4313CrossRefPubMedGoogle Scholar
  15. Stewart KD, Shiroda M, James CA (2006) Drug Guru: a computer software program for drug design using medicinal chemistry rules. Bioorg Med Chem 14:7011–7022CrossRefPubMedGoogle Scholar
  16. Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY, Zweifel BS, Seibert K (2000) 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 43:775–777CrossRefPubMedGoogle Scholar
  17. Tropsha A (2010) Best practices for QSAR model development, validation, and exploitation. Mol Inform 29:476–488CrossRefGoogle Scholar
  18. Weininger D (1988) SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules. J Chem Inf Comput Sci 28(1):31–36CrossRefGoogle Scholar
  19. Weininger D, Weininger A, Weininger JL (1989) SMILES. 2. Algorithm for generation of unique SMILES notation. J Chem Inf Comput Sci 29(2):97–101CrossRefGoogle Scholar
  20. Yilmaz N (2012) Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases. Arch Med Sci 8:138–153CrossRefPubMedPubMedCentralGoogle Scholar
  21. Zupan J, Gasteiger J (1999) Neural networks in chemistry and drug design, 2nd edn. Wiley-VCH, WeinheimGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Michael S. Lawless
    • 1
    Email author
  • Marvin Waldman
    • 1
  • Robert Fraczkiewicz
    • 1
  • Robert D. Clark
    • 1
  1. 1.Simulations Plus, Inc.LancasterUSA

Personalised recommendations